Trial · NCT03765229
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Conversions of Non-inflamed to Inflamed Melanoma | Single Arm: Entinostat + Pembrolizumab | Tumor-infiltrating lymphocyte increased | 3 | Participants | |
| Number of Conversions of Non-inflamed to Inflamed Melanoma | Single Arm: Entinostat + Pembrolizumab | Tumor-infiltrating lymphocyte not increased | 7 | Participants | |
| Overall Response Rate | Single Arm: Entinostat + Pembrolizumab | Complete Response or Partial Response | 3 | Participants | |
| Overall Response Rate | Single Arm: Entinostat + Pembrolizumab | Stable Disease or Progression | 8 | Participants | |
| Progression-Free Survival | Single Arm: Entinostat + Pembrolizumab | Alive with no evidence of disease | 1 | Participants | |
| Progression-Free Survival | Single Arm: Entinostat + Pembrolizumab | Alive with disease | 3 | Participants | |
| Progression-Free Survival | Single Arm: Entinostat + Pembrolizumab | Died from disease | 7 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | fatigue | 11 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | nausea | 6 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | vomiting | 3 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | diarrhea | 7 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | anorexia | 3 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | musculoskeletal pain | 5 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | cytopenia | 2 | Participants | |
| Number of Participant With Adverse Events During the Concurrent Pembrolizumab-entinostat Combination | Single Arm: Entinostat + Pembrolizumab | anemia | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03765229/results